antiplatelet 中文意思是什麼

antiplatelet 解釋
抗血小板的
  1. Evidence based case report should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy

    原發性腦出血患者是否應該進行抗血小板或抗凝治療
  2. Excellent teacher of china 1989 research fields : cellular signal transduction ; antitumor and antiplatelet drugs

    近年來，在省級以上核刊物發表文化教育文40多篇，其中第一作者15篇。
  3. The prevented and therapeutic approaches of the disease are suggested to be lipid - lowering, antiplatelet, thrombolytic drug and percutaneous coronary intervention ( pci ), respectively

    預防動脈血栓形成主要是降血脂和抗血小板黏附、聚集，而預防靜脈血栓形成則抗凝和採取措施減輕淤血。
  4. The researchers note that further studies are needed in patients not pretreated with antiplatelet agents, including those intolerant or allergic to aspirin or clopidogrel, and those with aspirin and / or clopidogrel resistance

    研究者指出，還需進一步對未使用抗血小板藥物的患者（包括不能耐受阿司匹林或氯吡格雷者、或對其過敏者，以及存在阿司匹林和/或氯吡格雷抵抗者）進行研究。
  5. In conclusion, antiplatelet prophylaxis can effectively reduce the incidence of late hat after lt, particularly in those patients at risk for this complication

    總之，抗血小板治療能有效的降低肝移植后遲發性肝動脈栓塞的發生率，特別是對那些存在該並發癥的危險的患者。
  6. The antiplatelet aggregation of micro capsule powder of enteric - characteristic plg

    腸溶性微囊粉的抗血小板聚集作用
  7. Study on antiplatelet effect of radix astragali total saponin combined with radix paeoniae rubra giucosides

    黃芪總皂苷和赤芍總苷協同抗血小板作用研究
  8. The researchers found the risks of developing preeclampsia dropped 10 percent among women taking aspirin or other antiplatelet medications

    研究者發現，相比于服用阿司匹林或者其它抗血小板藥物，患先兆子癇的概率下降了10 % 。
  9. It is well recognized that antiplatelet therapy is effective in the prevention and treatment of thrombosis

    摘要抗血小板治療可以有效預防和治療血栓性疾病，氯吡格雷是一種新型安全高效的抗血小板藥物。
  10. Thromboembolic eent rates were haled among the 159 aneurysms in patients treated with acetylsalicylic acid compared to the 102 aneurysms in patients treated without the antiplatelet agent, the study authors reported on thursday

    該研究的作者星期四報道， 159名使用阿司匹林的動脈瘤患者與102名未使用抗血小板治療的動脈瘤患者相比，血栓栓塞事件的發生率降低50 。
  11. About dual antiplatelet therapy, i might first choose aspirin + persantin ( aggrenox ). aspirin + clopidogrel have no evidence of clinical use in ischemic stroke without stenting procedure

    另外，關于這個病人的發病機制，也很難用某一單一的機制來解釋，這個病人不只是大動脈有問題，他還有很多小血管的問題。
  12. Background : anticoagulants and antiplatelet drugs ( e. g., warfarin, clopidogrel and acetylsalicylic acid ) are key therapeutic agents in the treatment of cardiovascular diseases

    背景：抗凝和抗血小板藥物（如華法令、氯吡格雷、阿司匹林）是治療心血管疾病的主要藥物。
  13. Six ariables stand out as important indicators of risk : ( 1 ) adanced age, ( 2 ) low preoperatie red blood cell olume ( preoperatie anemia or small body size ), ( 3 ) preoperatie antiplatelet or antithrombotic drugs, ( 4 ) reoperatie or complex procedures, ( 5 ) emergency operations, and noncardiac patient comorbidities

    它突出了作為重要風險指標的六個參量： （ 1 ）老年， （ 2 ）術前低血紅細胞比容（術前貧血或小體型貧血） ， （ 3 ）術前應用抗血小板或抗血栓形成藥， （ 4 ）再手術或復雜手術， （ 5 ）緊急手術， （ 6 ）非心血管病人的共病。
  14. Six variables stand out as important indicators of risk : ( 1 ) advanced age, ( 2 ) low preoperative red blood cell volume ( preoperative anemia or small body size ), ( 3 ) preoperative antiplatelet or antithrombotic drugs, ( 4 ) reoperative or complex procedures, ( 5 ) emergency operations, and noncardiac patient comorbidities

    它突出了作為重要風險指標的六個參量： （ 1 ）老年， （ 2 ）術前低血紅細胞比容（術前貧血或小體型貧血） ， （ 3 ）術前應用抗血小板或抗血栓形成藥， （ 4 ）再手術或復雜手術， （ 5 ）緊急手術， （ 6 ）非心血管病人的共病。
  15. The fda also recommends prolonged dual antiplatelet therapy for at least a year following the interention

    Fda也推薦介入治療后至少延長一年對病人進行雙重抗血小板治療。
  16. Anticoagulation use has increased in nontargeted, low - risk groups in whom antiplatelet agents are appropriate

    在那些接受抗血小板治療更加合適的低危險組病人中，抗凝治療的使用也呈增加趨勢。
  17. Hence, particularly for women at high risk of preeclampsia, a more widespread use of antiplatelet agents may be worthwhile, " she said

    因此，特別是對於她們來說，更廣泛地應用抗血小板藥物是值得的。 」
  18. They did not find nearly as strong a link between antiplatelet agents and ich as that between anticoagulation and hemorrhages, she added

    她補充說，他們發現抗血小板藥物與顱內出血發病之間的聯系並不如抗凝劑與出血事件之間的聯系那麼緊密。
  19. Compared with the control, adjusted - dose warfarin ( 6 trials, 2900 participants ) and antiplatelet agents ( 8 trials, 4876 participants ) reduced stroke by 64 % ( 95 % ci, 49 % to 74 % ) and 22 % ( ci, 6 % to 35 % ), respectiely

    與對照組相比，採用適量的華法林（ 6個試驗， 2900名受試者）和抗血小板藥物（ 8個試驗， 4876名受試者）抗凝治療的患者卒中發生率分別減少了64和22 。
  20. Conclusions : adjusted - dose warfarin and antiplatelet agents reduce stroke by approximately 60 % and by approximately 20 %, respectiely, in patients who hae atrial fibrillation. warfarin is substantially more efficacious ( by approximately 40 % ) than antiplatelet therapy

    結論：在房顫病人中，適量的華法林和抗血小板藥的抗凝治療分別減少了大約60和20的卒中發生率。而實際上，華法林比抗血小板治療更加有效（大約40 ） 。
分享友人
分享到 Line

分享到臉書